Indaptus Therapeutics Reports Net Loss of $7.5 Million for Q2 2023

Indaptus Therapeutics, Inc.(INDP), a prominent player in the biotech nology industry, has recently released its unaudited condensed consolidated financial statements for the second quarter of 2023. The financial data reveals a net loss of $7.5 million for the quarter, alongside a decrease in revenue compared to previous periods. The company's balance sheets, statements of operations, and other key financial metrics provide insights into its financial performance during this period.

Net Loss of $7.5 Million in Q2 2023

Indaptus Therapeutics, Inc. announced a net loss of $7.5 million for the second quarter of 2023. This loss reflects the company's operating expenses and other financial activities during this period. The financial statement shows that the company continues to invest in research and development, as well as general and administrative activities, impacting its bottom line.

Revenue Decline in Unaudited Financial Results for Q2 2023